All Stories

  1. The role of a best practice alert in the electronic medical record in reducing repetitive lab tests

    Article • ClinicoEconomics and Outcomes Research, October 2018, Dove Medical Press

    Lazarus Mramba, harini bejjanki

  2. Keep an Eye on the Eye Symptoms of your Dialysis Patient

    Article • The American Journal of Medicine, September 2018, Elsevier

    Dr Abhilash Koratala, harini bejjanki

  3. Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials

    Article • Oncotarget, May 2018, Impact Journals, LLC

    harini bejjanki

  4. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis

    Article • Leukemia & Lymphoma, February 2018, Taylor & Francis

    harini bejjanki

  5. An alternative approach with a low dose and prolonged chemotherapy for palliative treatment of locally advanced, metastatic or recurrent squamous cell head and neck cancer

    Article • Applied Cancer Research, December 2017, Springer Science + Business Media

    harini bejjanki

  6. Novel Mutation Pair L858M/L861Q Caused Resistance to Both First- and Third-Generation EGFR Inhibitors, but Was Found to Be Sensitive to the Combination of Lapatinib and Erbitux

    Article • Journal of Thoracic Oncology, October 2017, Elsevier

    harini bejjanki

  7. Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era

    Article • Journal of Gastrointestinal Oncology, October 2017, AME Publishing Company

    harini bejjanki

  8. Reno-vascular toxicities associated with carfilzomib: Systematic review and meta-analysis.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    harini bejjanki

  9. Cardiotoxicity associated with carfilzomib: Systematic review and meta-analysis.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    harini bejjanki

  10. Survival and side effects from novel alternative regimen for squamous cell head and neck cancer.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    harini bejjanki

  11. Survival difference among patients with hepatocelluar carcinoma (HCC) based on stage of disease: The pre- and post-sorafenib era.

    Article • Journal of Clinical Oncology, February 2017, American Society of Clinical Oncology (ASCO)

    harini bejjanki